Can-Fite BioPharma plans to develop Piclidenoson for treatment of Lowe Syndrome

Can-Fite BioPharma announced it plans to develop its drug candidate, Piclidenoson, for the treatment of Lowe Syndrome based on recent efficacy findings at the University of Naples Federico II, and Program Coordinator of the Cell Biology and Disease Mechanisms at The Telethon Institute of Genetics and Medicine, or TIGEM, in Italy. Can-Fite and Fondazione Telethon have signed an agreement outlining their collaboration for the development of Piclidenoson for the treatment of Lowe Syndrome, a high medical need with no drug available. Fondazione Telethon is an Italian nonprofit organization whose mission is to advance biomedical research toward the diagnosis, cure, and prevention of genetic diseases, and it established TIGEM in 1994.